Back to Search
Start Over
New onset diabetes mellitus and cardiovascular events in Korean patients with acute myocardial infarction receiving high-intensity statins
- Source :
- BMC Pharmacology & Toxicology, BMC Pharmacology and Toxicology, Vol 22, Iss 1, Pp 1-7 (2021)
- Publication Year :
- 2021
- Publisher :
- Springer Science and Business Media LLC, 2021.
-
Abstract
- Background High-intensity statin therapy is typically used in patients with acute myocardial infarction (AMI) for secondary prevention. However, there have been consistent concerns regarding its association with diabetes mellitus. We investigated the effect of high-intensity atorvastatin and rosuvastatin on new-onset diabetes mellitus (NODM) and cardiovascular outcomes over a 3-year follow-up period. Methods Data from the Korea Acute Myocardial Infarction Registry were collected from November 2011 to October 2015, and 13,104 patients with AMI were enrolled from major cardiovascular centers. Among them, 2221 patients without diabetes who had been administered with high-intensity atorvastatin (40–80 mg) and rosuvastatin (20 mg) were investigated. The atorvastatin and rosuvastatin groups were evaluated for the incidence of NODM and major adverse cardiac events (MACE) including death, myocardial infarction, and revascularization cases in the following 3 years. Results Baseline characteristics were comparable between the two groups. Event-free survival rate of NODM was not significantly different between the atorvastatin and rosuvastatin groups (92.5% vs. 90.8%, respectively; Log-rank P-value = 0.550). The event-free survival rate of MACE was also not significantly different between atorvastatin and rosuvastatin groups (89.0% vs. 89.6%, respectively; Log rank P-value = 0.662). Multivariate Cox analysis revealed that statin type was not a prognostic factor in the development of NODM and MACE. Conclusions Administering high-intensity atorvastatin and rosuvastatin in patients with AMI produced comparable effects on NODM and clinical outcomes, suggesting their clinical equivalence in secondary prevention.
- Subjects :
- Male
medicine.medical_treatment
Atorvastatin
030204 cardiovascular system & hematology
0302 clinical medicine
Secondary Prevention
Pharmacology (medical)
Registries
030212 general & internal medicine
Myocardial infarction
Rosuvastatin Calcium
Middle Aged
Treatment Outcome
Cardiovascular Diseases
Cardiology
Female
Research Article
medicine.drug
medicine.medical_specialty
Statin
medicine.drug_class
Hypercholesterolemia
Acute myocardial infarction
Revascularization
Rosuvastatin
03 medical and health sciences
Asian People
lcsh:RA1190-1270
Diabetes mellitus
Internal medicine
Republic of Korea
Diabetes Mellitus
medicine
Humans
cardiovascular diseases
Survival rate
lcsh:Toxicology. Poisons
Aged
Pharmacology
business.industry
lcsh:RM1-950
nutritional and metabolic diseases
Cardiovascular outcome
medicine.disease
lcsh:Therapeutics. Pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors
New-onset diabetes mellitus
business
Mace
Subjects
Details
- ISSN :
- 20506511
- Volume :
- 22
- Database :
- OpenAIRE
- Journal :
- BMC Pharmacology and Toxicology
- Accession number :
- edsair.doi.dedup.....f76a59adb89637eb0bc7985cbac7292d